Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Adds To Unapproved Drug Initiative Scorecard With Action Against KV

Executive Summary

Two weeks after FDA officials attempted to explain how well the Center for Drug Evaluation and Research's unapproved drug initiative is working, the agency showed how action often speaks louder than words

You may also be interested in...

KV Pharmaceutical Pledges To Improve Finances, But NYSE Demands Action

Already plagued by scandal, KV Pharma is subject to NYSE delisting if overdue 2009 annual report is not filed soon.

KV Pharmaceutical Enters Consent Decree With FDA In Move To Resume Manufacturing

Certain products will not be distributed until approved via NDA or ANDA processes.

Gestiva Approval Unlikely In FY 09; KV Pharmaceutical Admits Credit Fumbles

Firm halts manufacturing and distribution of nearly all products.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts